Gerresheimer’s glass and plastic prefillable syringes will come with an innovative, integrated, passive syringe safety solution, acquired through an exclusive licence from West Pharmaceutical Services.
Gerresheimer announced that it will complete its product portfolio of prefillable syringes made of glass and plastics with an innovative, integrated, passive syringe safety solution, acquired through an exclusive licence from West Pharmaceutical Services.
“As a result of our long-standing partnership with the leading manufacturer of packaging components and delivery devices for parenteral drugs, we are pleased to have acquired the rights to market this innovative, new syringe safety solution, developed by West. By doing so, we will complement our very broad range of prefillable syringe solutions for biotech and other drugs,” said Uwe Röhrhoff, CEO of Gerresheimer AG, in a press statement.
Gerresheimer supplies prefillable syringes made of glass and plastics. The new safety solution is fully compatible with Gerresheimer’s well-established ready-to-fill (RTF) syringe portfolio. The solution is fully integrated and will be assembled on the syringe in the run of the RTF production process. Pharmaceutical manufacturers will be able to use the standard filling process as the new syringe safety solution is compliant with standard nests and tubs.
There is increasing demand for innovative safety solutions given the prevalence of needlestick-related injuries among healthcare workers and patients. The new Gerresheimer integrated safety syringe will address this need by offering improved syringe processability and high-end user friendliness.
Source: Gerresheimer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.